Boston Scientific is set to release its second-quarter earnings on July 29, with investors closely watching its heart device segment and the impact of a newly approved restructuring plan. The company’s shares were trading at $45.55, well below the average analyst price target of $72.25.
The recently announced restructuring, approved by the board on July 21, is a sweeping initiative expected to cost between $700 million and $800 million before taxes, mostly paid in cash. This plan will reshape the company’s supply chain, shift production across factories, and include job cuts, although hiring will continue in growth areas. The overhaul is scheduled to unfold through the end of 2029 and aims to deliver annual savings of about $500 million, which Boston Scientific intends to funnel back into growth projects.
Performance and Market Expectations
Wall Street expects Boston Scientific’s revenue to grow 5.9% year over year in this quarter, a slowdown from the 22.8% surge reported during the same period last year. The company has a history of surpassing analyst expectations, which adds an element of anticipation to this report. Last quarter, Boston Scientific posted $5.20 billion in revenue, beating forecasts by 11.6%, although the outlook for the next quarter came in lower than expected.
Peers in the healthcare equipment sector have already reported mixed results. Abbott Laboratories reported a 13% revenue increase, lifting its stock by nearly 13%, while Intuitive Surgical beat revenue estimates with an 18.5% rise but saw its shares fall by over 14%. This uneven investor reaction indicates uncertainty ahead of Boston Scientific’s earnings announcement.
The stock jumped 2.85% following the restructuring news, reflecting cautious optimism. Analysts have mostly maintained their earnings estimates over the past month, highlighting confidence in the company's ability to navigate this transition.
material is for informational purposes only and is not financial advice
